Amylyx Pharmaceutical
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 22.2m | 381m | 102m | <1m | <1m |
| % growth | - | - | - | 1613 % | (73 %) | (100 %) | 97 % |
| EBITDA | (38.7m) | (82.7m) | (201m) | 39.9m | (310m) | (180m) | (237m) |
| % EBITDA margin | - | - | (906 %) | 10 % | (305 %) | (108098 %) | (72067 %) |
| Profit | (42.3m) | (87.9m) | (198m) | 49.3m | (233m) | (109m) | (82.7m) |
| % profit margin | - | - | (892 %) | 13 % | (229 %) | (65567 %) | (25140 %) |
| EV / revenue | - | - | 94.5x | 1.6x | 1.1x | 799.0x | 124.3x |
| EV / EBITDA | - | - | -10.4x | 15.6x | -0.4x | -0.7x | -0.2x |
| R&D budget | 24.6m | 44.0m | 93.5m | 128m | - | - | - |
| R&D % of revenue | - | - | 420 % | 34 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $1.4m | Early VC | |
$5.0m | Series A | ||
| N/A | $13.0m | Debt | |
| N/A | $14.8m | Debt | |
$30.0m | Series B | ||
$135m | Series C | ||
* | N/A | $190m | IPO |
* | N/A | $246m | Post IPO Equity |
| Total Funding | $171m | ||
Related Content
Recent News about Amylyx Pharmaceutical
EditAmylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, specifically Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). The company operates in the healthcare sector, targeting patients, caregivers, healthcare providers, and researchers as its primary clients.
Amylyx's flagship product, AMX0035, is under rigorous clinical evaluation. The CENTAUR ALS trial, a 24-week Phase II clinical trial, demonstrated significant treatment benefits for ALS patients. This trial was randomized, double-blind (neither participants nor researchers know who is receiving the treatment), and placebo-controlled (some participants receive a non-active substance to compare results). The positive results from this trial have been published in reputable medical journals, including the New England Journal of Medicine and Muscle Nerve.
Additionally, Amylyx is conducting the PEGASUS trial, which is another randomized, double-blind, placebo-controlled study. This trial focuses on evaluating the safety and effectiveness of AMX0035 in patients with late mild cognitive impairment or early dementia due to Alzheimer's Disease over a 24-week period.
Amylyx's business model revolves around the research and development of innovative treatments, followed by clinical trials to prove their efficacy and safety. Once these treatments are approved by regulatory bodies, the company plans to commercialize them, generating revenue through sales to healthcare providers and patients.
The company also engages in awareness campaigns, such as ALS Awareness Month, to educate the public and unite communities in the fight against these debilitating diseases. This not only helps in spreading awareness but also in building a supportive community around their cause.
In summary, Amylyx Pharmaceuticals is dedicated to advancing treatments for neurodegenerative diseases through rigorous clinical trials and community engagement, aiming to bring effective therapies to market and improve patient outcomes.
Keywords: Biopharmaceutical, ALS, Alzheimer's, AMX0035, Clinical Trials, Neurodegenerative, Healthcare, Research, Treatment, Awareness.